Labcorp Perspectives Oncology (Episode 11): Advancing endometrial cancer care with molecular profiling

In this episode of Labcorp Perspectives: Oncology, Dr. Rebecca Previs sits down with Drs. Aine Clements and Angeles Alvarez Secord to revisit the landmark GOG‑258 trial through a modern molecular lens. Together, they explore how integrating biomarkers such as POLE, mismatch repair, and p53 is reshaping our understanding of prognosis and treatment in advanced endometrial cancer.

Their discussion highlights how molecular classification is uncovering distinct patient subgroups—particularly those with POLE mutations, who demonstrate exceptional outcomes—and how these insights may inform more personalized, and potentially less intensive, treatment strategies. As the field continues to evolve, this episode underscores the growing importance of precision oncology in guiding clinical decision-making and improving patient care.